retatrutide type 2 diabetes phase 2 trial for Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with diabetes: a randomised, double-blind, placebo and retatrutide type 2 diabetes phase

My shot day, time & dosage, any side effects I may have, my weight etc

For a smaller group of patients, symptoms interfere with work, sleep, and social activities

The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance

Molecular portraits of human breast tumours

Regulatory Status GLP-3 (Reta) (LY3437943) is an investigational compound developed by Eli Lilly

Interventions: Drug: Tavapadon Drug: Placebo Primary Outcome Measures: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) retains the four-scale structure with a reorganization of the various subscales